Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes：a Phase II Single-arm Study

NCT06490913 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT06490913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06490913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes：a Phase II Single-arm Study
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
November 1, 2024
Completion date
December 31, 2025
Enrollment
33 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

liver metastases of colorectal cancer